FDA Asked To Probe 3M's MRSA Clinical Test Conduct

Law360, New York (May 11, 2011, 4:27 PM EDT) -- Private equity firm Porton Group said Wednesday that it would ask the U.S. Food and Drug Administration to investigate 3M Co.'s alleged mishandling of clinical trials for a MRSA detection device that harmed marketing plans for the product at an alleged loss to U.K. investors.

Porton is already suing 3M in the U.K. for breach of contract over its handling of the BacLite test and U.S. clinical trials in 2007 that led to poor 50 percent reliability results, according to Robert R. Hopper, an attorney for...
To view the full article, register now.